1. Home
  2. IMOS vs PHAT Comparison

IMOS vs PHAT Comparison

Compare IMOS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMOS

ChipMOS TECHNOLOGIES INC.

HOLD

Current Price

$27.94

Market Cap

980.5M

Sector

Technology

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$14.67

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMOS
PHAT
Founded
1997
2018
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.5M
942.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
IMOS
PHAT
Price
$27.94
$14.67
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.60
AVG Volume (30 Days)
24.1K
812.6K
Earning Date
11-11-2025
10-30-2025
Dividend Yield
2.29%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$748,307,671.00
$147,190,000.00
Revenue This Year
$5.78
$218.59
Revenue Next Year
$10.84
$84.38
P/E Ratio
$129.31
N/A
Revenue Growth
N/A
460.30
52 Week Low
$12.78
$2.21
52 Week High
$30.98
$16.27

Technical Indicators

Market Signals
Indicator
IMOS
PHAT
Relative Strength Index (RSI) 59.98 53.42
Support Level $27.55 $14.61
Resistance Level $28.36 $16.27
Average True Range (ATR) 0.89 0.77
MACD -0.26 -0.10
Stochastic Oscillator 53.45 21.91

Price Performance

Historical Comparison
IMOS
PHAT

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: